Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal atropine olfactory stress test for cognitive decline and incident Alzheimer's disease
ACTRN12617000273381Phase 2Completed
- Sponsor
- Dr. Peter Schofield
- Start
- Jun 2017
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atropine in Alzheimer's disease (AD), confusion and No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity, sponsored by Dr. Peter Schofield. Primary endpoints: Cognitive decline on the Audio Recorded Cognitive Screen, Incident dementia due to Alzheimer's disease and 1 more. Started Jun 2017; status: completed.
02
Drugs
atropine
03
Conditions
Alzheimer's disease (AD)confusionNo canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on ACTRN12617000273381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000273381.